InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Stock Down 1.9 %

NSPR stock opened at $2.64 on Thursday. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.80. The company has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $2.75. The firm has a market capitalization of $78.38 million, a P/E ratio of -3.52 and a beta of 0.74.

Hedge Funds Weigh In On InspireMD

A number of hedge funds have recently added to or reduced their stakes in NSPR. Parkman Healthcare Partners LLC grew its holdings in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after acquiring an additional 750,635 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in InspireMD during the 4th quarter worth $191,000. Northern Trust Corp increased its holdings in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after acquiring an additional 24,452 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its stake in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new position in shares of InspireMD in the 4th quarter valued at $47,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.